Blog
RSS FeedPosted by Michael Wonder on 08 Oct 2020
NDA submission for Polarean’s hyperpolarised 129 Xenon gas drug-device diagnostic for lung imaging
7 October 2020 - Polarean Imaging announces its submission of a new drug application and request for priority review to the ...
Posted by Michael Wonder on 07 Oct 2020
Eli Lilly asks FDA to authorise COVID-19 antibody drug
7 October 2020 - Company says it could supply one million doses of the treatment this year, if regulator authorises emergency ...
Posted by Michael Wonder on 07 Oct 2020
Eton Pharmaceuticals submits new drug application to the FDA for topiramate oral solution
6 October 2020 - Application submitted for the treatment of partial-onset seizures and migraine. ...
Posted by Michael Wonder on 06 Oct 2020
Y-mAbs provides regulatory update on omburtamab for the treatment of patients with neuroblastoma
5 October 2020 - Y-mAbs Therapeutics today announced that Y-mAbs has received a Refusal to File letter from the U.S. FDA ...
Posted by Michael Wonder on 02 Oct 2020
Provention Bio files clinical module for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals
30 September 2020 - Expect to complete filing of the rolling biologics license application for teplizumab in Q4 2020. ...
Posted by Michael Wonder on 02 Oct 2020
Lantheus submits new drug application to the U.S. FDA for PyL (18F DCFPyL), a PSMA targeted prostate cancer imaging agent
30 September 2020 - Sep. 30, 2020-- Lantheus today announced the submission of a new drug application to the U.S. FDA ...
Posted by Michael Wonder on 01 Oct 2020
Kadmon announces submission of new drug application to the U.S. FDA for belumosudil in patients with chronic graft versus host disease
30 September 2020 - Application being reviewed under FDA's Real-Time Oncology Review pilot program. ...
Posted by Michael Wonder on 30 Sep 2020
Janssen submits new drug application to U.S. FDA for Uptravi (selexipag) injection for intravenous use to treat pulmonary arterial hypertension
30 September 2020 - Janssen today announced the submission of a new drug application to the U.S. FDA for Uptravi ...
Posted by Michael Wonder on 29 Sep 2020
BridgeBio Pharma and affiliate Origin Biosciences announces FDA acceptance of its new drug application for fosdenopterin for the treatment of MoCD type A
29 September 2020 - Application accepted under priority review designation with breakthrough therapy designation and rare paediatric disease designation previously granted. ...
Posted by Michael Wonder on 24 Sep 2020
Telix Pharmaceuticals submits new drug application to US FDA for prostate cancer imaging product
24 September 2020 - Telix Pharmaceuticals today announces it has submitted a new drug application to the United States FDA for ...
Posted by Michael Wonder on 23 Sep 2020
FDA accepts supplemental new drug application for Pfizer’s Xalkori (crizotinib) for the treatment of paediatric ALK positive anaplastic large cell lymphoma
23 September 2020 - If approved, Xalkori would be the first biomarker driven therapy for paediatric ALK positive anaplastic large cell ...
Posted by Michael Wonder on 23 Sep 2020
UCB achieves important regulatory milestone for bimekizumab
22 September 2020 - The U.S. FDA and EMA have accepted marketing application submissions for bimekizumab for the treatment of adults ...
Posted by Michael Wonder on 23 Sep 2020
Liminal BioSciences provides update on progress on BLA for Ryplazim (plasminogen)
21 September 2020 - FDA assigns PDUFA target action date of 5 March 2021. ...
Posted by Michael Wonder on 22 Sep 2020
Hikma updates on ANDA for generic Advair Diskus
22 September 2020 - Hikma Pharmaceuticals announces that it has received a minor complete response letter from the US FDA ...
Posted by Michael Wonder on 22 Sep 2020
U.S. FDA accepts for priority review Bristol Myers Squibb and bluebird bio application for anti-BCMA CAR T-cell therapy idecabtagene vicleucel (Ide-cel, bb2121)
22 September 2020 - Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma. ...